Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
RESEARCH TOOLSreports
Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis
73 Followers
LXEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.00 - $22.33
Previous Close$13.72
Volume245.66K
Average Volume (3M)119.75K
Market Cap
$365.58M
Enterprise Value$332.70M
Total Cash (Recent Filing)$45.54M
Total Debt (Recent Filing)$12.66M
Price to Earnings (P/E)-5.5
Beta1.76
Next Earnings
May 09, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding26,668,956
10 Day Avg. Volume150,243
30 Day Avg. Volume119,747
Standard Deviation0.19
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.49
Price to Sales (P/S)559.48
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit508.71
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.33Price Target Upside47.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Lexeo Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Pipeline PotentialAnalyst recommends a Buy rating for Lexeo Therapeutics based on the potential of its gene therapy pipeline to address the root causes of certain cardiomyopathies and Alzheimer’s disease, with substantial markets and unmet needs.
Regulatory EnvironmentLexeo's cardiovascular gene therapy programs may benefit from a favorable regulatory environment, as evidenced by the positive implications from similar therapies in the space.
Strategic PartnershipsLexeo Therapeutics' Alzheimer's disease franchise is poised to attract partnership opportunities, leveraging upcoming clinical data to potentially unlock near-term value.
Bears Say
Drug EfficacyCritical questions remain about the effectiveness of the company's key drug, casting doubt on its future market success and impact on share value.
Regulatory ChallengesOngoing uncertainty in the regulatory approval process may dampen investor confidence and delay potential revenue streams for the company.
Research And Development ExpensesThe company's R&D spending has significantly exceeded estimates, signaling potential concerns over cost management and profitability.
---
Ownership Overview
25.52% Insiders
10.75% Mutual Funds
3.52% Other Institutional Investors
60.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $9.00 and its highest was $22.33 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is May 09, 2024 which is yesterday.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Mar 11, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.697 by -$0.163.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -$0.74.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 26,645,538 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.697. Following the earnings report the stock price went up 5.685%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Among the largest hedge funds holding Lexeo Therapeutics, Inc.’s share is D1 Capital Partners LP. It holds Lexeo Therapeutics, Inc.’s shares valued at 34M.
---
Lexeo Therapeutics, Inc. Stock Smart Score
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
---
LXEO Stock 12 Month Forecast
Average Price Target
$21.33
▲(47.10% Upside)
Technical Analysis
Best Analysts Covering LXEO
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+14.63%
reiterated a buy rating 17 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +14.63% per trade.
---